Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
215
-
Total 13F shares, excl. options
-
126M
-
Shares change
-
+1.2M
-
Total reported value, excl. options
-
$3.68B
-
Value change
-
+$76.2M
-
Put/Call ratio
-
0.39
-
Number of buys
-
109
-
Number of sells
-
-81
-
Price
-
$29.13
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q3 2024
245 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q3 2024.
Denali Therapeutics Inc. - Common Stock (DNLI) has 215 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 126M shares
of 145M outstanding shares and own 86.99% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (13.8M shares), BAILLIE GIFFORD & CO (13.3M shares), VANGUARD GROUP INC (11.2M shares), WELLINGTON MANAGEMENT GROUP LLP (10.7M shares), Capital Research Global Investors (7.91M shares), FMR LLC (7.83M shares), Temasek Holdings (Private) Ltd (5.36M shares), Crestline Management, LP (4.46M shares), STATE STREET CORP (4.25M shares), and UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (3.75M shares).
This table shows the top 215 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.